http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 05 May 2025 07:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Aptose+Provides+Clinical+Update+for+the+Tuspetinib-based+Triple+Drug+Frontline+Therapy+in+Newly+Diagnosed+AML+Patients+from+the+Phase+12+TUSCANY+Trial/24738620.html <p align="center"><em>Aptose is developing TUS+VEN+AZA as a one-of-a-kind safe and mutation agnostic frontline triple drug therapy for newly diagnosed AML patients</em></p> <p align="center"><em>First two dose cohorts of TUS+VEN+AZA triplet demonstrate safety, complete remissions, and MRD negativity across patients with diverse mutations, including TP53-mutated/CK AML and FLT3-wildtype AML patients</em></p> <p align="justify">SAN DIEGO and TORONTO, May 05, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company, today reported updated and new data from Aptose’s Phase 1/2 TUSCANY trial in newly diagnosed acute myeloid leukemia (AML) patients dosed http://www.streetinsider.com/Press+Releases/Aptose+Provides+Clinical+Update+for+the+Tuspetinib-based+Triple+Drug+Frontline+Therapy+in+Newly+Diagnosed+AML+Patients+from+the+Phase+12+TUSCANY+Trial/24738620.html Mon, 05 May 2025 07:00:00 -0400 APS APTO O.00674004 http://www.streetinsider.com/Press+Releases/Aptose+Provides+Clinical+Update+for+the+Tuspetinib-based+Triple+Drug+Frontline+Therapy+in+Newly+Diagnosed+AML+Patients+from+the+Phase+12+TUSCANY+Trial/24738620.html <p align="center"><em>Aptose is developing TUS+VEN+AZA as a one-of-a-kind safe and mutation agnostic frontline triple drug therapy for newly diagnosed AML patients</em></p> <p align="center"><em>First two dose cohorts of TUS+VEN+AZA triplet demonstrate safety, complete remissions, and MRD negativity across patients with diverse mutations, including TP53-mutated/CK AML and FLT3-wildtype AML patients</em></p> <p align="justify">SAN DIEGO and TORONTO, May 05, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company, today reported updated and new data from Aptose’s Phase 1/2 TUSCANY trial in newly diagnosed acute myeloid leukemia (AML) patients dosed http://www.streetinsider.com/Press+Releases/Aptose+Provides+Clinical+Update+for+the+Tuspetinib-based+Triple+Drug+Frontline+Therapy+in+Newly+Diagnosed+AML+Patients+from+the+Phase+12+TUSCANY+Trial/24738620.html Mon, 05 May 2025 07:00:00 -0400 APS APTO O.00674004 http://www.streetinsider.com/Press+Releases/Aptose+Provides+Clinical+Update+for+the+Tuspetinib-based+Triple+Drug+Frontline+Therapy+in+Newly+Diagnosed+AML+Patients+from+the+Phase+12+TUSCANY+Trial/24738620.html <p align="center"><em>Aptose is developing TUS+VEN+AZA as a one-of-a-kind safe and mutation agnostic frontline triple drug therapy for newly diagnosed AML patients</em></p> <p align="center"><em>First two dose cohorts of TUS+VEN+AZA triplet demonstrate safety, complete remissions, and MRD negativity across patients with diverse mutations, including TP53-mutated/CK AML and FLT3-wildtype AML patients</em></p> <p align="justify">SAN DIEGO and TORONTO, May 05, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company, today reported updated and new data from Aptose’s Phase 1/2 TUSCANY trial in newly diagnosed acute myeloid leukemia (AML) patients dosed http://www.streetinsider.com/Press+Releases/Aptose+Provides+Clinical+Update+for+the+Tuspetinib-based+Triple+Drug+Frontline+Therapy+in+Newly+Diagnosed+AML+Patients+from+the+Phase+12+TUSCANY+Trial/24738620.html Mon, 05 May 2025 07:00:00 -0400 APS APTO O.00674004 http://www.streetinsider.com/Globe+Newswire/Aptose+Provides+Clinical+Update+for+the+Tuspetinib-based+Triple+Drug+Frontline+Therapy+in+Newly+Diagnosed+AML+Patients+from+the+Phase+12+TUSCANY+Trial/24738620.html <p align="center"><em>Aptose is developing TUS+VEN+AZA as a one-of-a-kind safe and mutation agnostic frontline triple drug therapy for newly diagnosed AML patients</em></p> <p align="center"><em>First two dose cohorts of TUS+VEN+AZA triplet demonstrate safety, complete remissions, and MRD negativity across patients with diverse mutations, including TP53-mutated/CK AML and FLT3-wildtype AML patients</em></p> <p align="justify">SAN DIEGO and TORONTO, May 05, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company, today reported updated and new data from Aptose’s Phase 1/2 TUSCANY trial in newly diagnosed acute myeloid leukemia (AML) patients dosed http://www.streetinsider.com/Globe+Newswire/Aptose+Provides+Clinical+Update+for+the+Tuspetinib-based+Triple+Drug+Frontline+Therapy+in+Newly+Diagnosed+AML+Patients+from+the+Phase+12+TUSCANY+Trial/24738620.html Mon, 05 May 2025 07:00:00 -0400 APS APTO O.00674004 http://www.streetinsider.com/Globe+Newswire/Aptose+Provides+Clinical+Update+for+the+Tuspetinib-based+Triple+Drug+Frontline+Therapy+in+Newly+Diagnosed+AML+Patients+from+the+Phase+12+TUSCANY+Trial/24738620.html <p align="center"><em>Aptose is developing TUS+VEN+AZA as a one-of-a-kind safe and mutation agnostic frontline triple drug therapy for newly diagnosed AML patients</em></p> <p align="center"><em>First two dose cohorts of TUS+VEN+AZA triplet demonstrate safety, complete remissions, and MRD negativity across patients with diverse mutations, including TP53-mutated/CK AML and FLT3-wildtype AML patients</em></p> <p align="justify">SAN DIEGO and TORONTO, May 05, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company, today reported updated and new data from Aptose’s Phase 1/2 TUSCANY trial in newly diagnosed acute myeloid leukemia (AML) patients dosed http://www.streetinsider.com/Globe+Newswire/Aptose+Provides+Clinical+Update+for+the+Tuspetinib-based+Triple+Drug+Frontline+Therapy+in+Newly+Diagnosed+AML+Patients+from+the+Phase+12+TUSCANY+Trial/24738620.html Mon, 05 May 2025 07:00:00 -0400 APS APTO O.00674004 http://www.streetinsider.com/Globe+Newswire/Aptose+Provides+Clinical+Update+for+the+Tuspetinib-based+Triple+Drug+Frontline+Therapy+in+Newly+Diagnosed+AML+Patients+from+the+Phase+12+TUSCANY+Trial/24738620.html <p align="center"><em>Aptose is developing TUS+VEN+AZA as a one-of-a-kind safe and mutation agnostic frontline triple drug therapy for newly diagnosed AML patients</em></p> <p align="center"><em>First two dose cohorts of TUS+VEN+AZA triplet demonstrate safety, complete remissions, and MRD negativity across patients with diverse mutations, including TP53-mutated/CK AML and FLT3-wildtype AML patients</em></p> <p align="justify">SAN DIEGO and TORONTO, May 05, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company, today reported updated and new data from Aptose’s Phase 1/2 TUSCANY trial in newly diagnosed acute myeloid leukemia (AML) patients dosed http://www.streetinsider.com/Globe+Newswire/Aptose+Provides+Clinical+Update+for+the+Tuspetinib-based+Triple+Drug+Frontline+Therapy+in+Newly+Diagnosed+AML+Patients+from+the+Phase+12+TUSCANY+Trial/24738620.html Mon, 05 May 2025 07:00:00 -0400 APS APTO O.00674004 http://www.streetinsider.com/Press+Releases/Aptose+Announces+Auditor+Not+Standing+for+Re-Appointment/24676773.html <p align="justify">SAN DIEGO and TORONTO, April 23, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX:APS), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), announces that effective on April 15, 2025, KPMG LLP, the current independent registered public accounting firm of the Company (the “KPMG”), informed the Company that it will not stand for re-appointment for the Company’s 2025 annual audit. The Company anticipates that KPMG will continue to review its quarterly interim financial results through the first two http://www.streetinsider.com/Press+Releases/Aptose+Announces+Auditor+Not+Standing+for+Re-Appointment/24676773.html Wed, 23 Apr 2025 17:00:00 -0400 A.21388897 A.36549092 APS APTO O.00674004 O.01848302 O.48400419 http://www.streetinsider.com/Press+Releases/Aptose+Announces+Auditor+Not+Standing+for+Re-Appointment/24676773.html <p align="justify">SAN DIEGO and TORONTO, April 23, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX:APS), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), announces that effective on April 15, 2025, KPMG LLP, the current independent registered public accounting firm of the Company (the “KPMG”), informed the Company that it will not stand for re-appointment for the Company’s 2025 annual audit. The Company anticipates that KPMG will continue to review its quarterly interim financial results through the first two http://www.streetinsider.com/Press+Releases/Aptose+Announces+Auditor+Not+Standing+for+Re-Appointment/24676773.html Wed, 23 Apr 2025 17:00:00 -0400 A.21388897 A.36549092 APS APTO O.00674004 O.01848302 O.48400419 http://www.streetinsider.com/Press+Releases/Aptose+Announces+Auditor+Not+Standing+for+Re-Appointment/24676773.html <p align="justify">SAN DIEGO and TORONTO, April 23, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX:APS), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), announces that effective on April 15, 2025, KPMG LLP, the current independent registered public accounting firm of the Company (the “KPMG”), informed the Company that it will not stand for re-appointment for the Company’s 2025 annual audit. The Company anticipates that KPMG will continue to review its quarterly interim financial results through the first two http://www.streetinsider.com/Press+Releases/Aptose+Announces+Auditor+Not+Standing+for+Re-Appointment/24676773.html Wed, 23 Apr 2025 17:00:00 -0400 A.21388897 A.36549092 APS APTO O.00674004 O.01848302 O.48400419 http://www.streetinsider.com/Press+Releases/Aptose+Announces+Auditor+Not+Standing+for+Re-Appointment/24676773.html <p align="justify">SAN DIEGO and TORONTO, April 23, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX:APS), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), announces that effective on April 15, 2025, KPMG LLP, the current independent registered public accounting firm of the Company (the “KPMG”), informed the Company that it will not stand for re-appointment for the Company’s 2025 annual audit. The Company anticipates that KPMG will continue to review its quarterly interim financial results through the first two http://www.streetinsider.com/Press+Releases/Aptose+Announces+Auditor+Not+Standing+for+Re-Appointment/24676773.html Wed, 23 Apr 2025 17:00:00 -0400 A.21388897 A.36549092 APS APTO O.00674004 O.01848302 O.48400419 http://www.streetinsider.com/Press+Releases/Aptose+Announces+Auditor+Not+Standing+for+Re-Appointment/24676773.html <p align="justify">SAN DIEGO and TORONTO, April 23, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX:APS), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), announces that effective on April 15, 2025, KPMG LLP, the current independent registered public accounting firm of the Company (the “KPMG”), informed the Company that it will not stand for re-appointment for the Company’s 2025 annual audit. The Company anticipates that KPMG will continue to review its quarterly interim financial results through the first two http://www.streetinsider.com/Press+Releases/Aptose+Announces+Auditor+Not+Standing+for+Re-Appointment/24676773.html Wed, 23 Apr 2025 17:00:00 -0400 A.21388897 A.36549092 APS APTO O.00674004 O.01848302 O.48400419 http://www.streetinsider.com/Press+Releases/Aptose+Announces+Auditor+Not+Standing+for+Re-Appointment/24676773.html <p align="justify">SAN DIEGO and TORONTO, April 23, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX:APS), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), announces that effective on April 15, 2025, KPMG LLP, the current independent registered public accounting firm of the Company (the “KPMG”), informed the Company that it will not stand for re-appointment for the Company’s 2025 annual audit. The Company anticipates that KPMG will continue to review its quarterly interim financial results through the first two http://www.streetinsider.com/Press+Releases/Aptose+Announces+Auditor+Not+Standing+for+Re-Appointment/24676773.html Wed, 23 Apr 2025 17:00:00 -0400 A.21388897 A.36549092 APS APTO O.00674004 O.01848302 O.48400419 http://www.streetinsider.com/Press+Releases/Aptose+Announces+Auditor+Not+Standing+for+Re-Appointment/24676773.html <p align="justify">SAN DIEGO and TORONTO, April 23, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX:APS), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), announces that effective on April 15, 2025, KPMG LLP, the current independent registered public accounting firm of the Company (the “KPMG”), informed the Company that it will not stand for re-appointment for the Company’s 2025 annual audit. The Company anticipates that KPMG will continue to review its quarterly interim financial results through the first two http://www.streetinsider.com/Press+Releases/Aptose+Announces+Auditor+Not+Standing+for+Re-Appointment/24676773.html Wed, 23 Apr 2025 17:00:00 -0400 A.21388897 A.36549092 APS APTO O.00674004 O.01848302 O.48400419 http://www.streetinsider.com/Globe+Newswire/Aptose+Announces+Auditor+Not+Standing+for+Re-Appointment/24676773.html <p align="justify">SAN DIEGO and TORONTO, April 23, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX:APS), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), announces that effective on April 15, 2025, KPMG LLP, the current independent registered public accounting firm of the Company (the “KPMG”), informed the Company that it will not stand for re-appointment for the Company’s 2025 annual audit. The Company anticipates that KPMG will continue to review its quarterly interim financial results through the first two http://www.streetinsider.com/Globe+Newswire/Aptose+Announces+Auditor+Not+Standing+for+Re-Appointment/24676773.html Wed, 23 Apr 2025 17:00:00 -0400 A.21388897 A.36549092 APS APTO O.00674004 O.01848302 O.48400419 http://www.streetinsider.com/Globe+Newswire/Aptose+Announces+Auditor+Not+Standing+for+Re-Appointment/24676773.html <p align="justify">SAN DIEGO and TORONTO, April 23, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX:APS), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), announces that effective on April 15, 2025, KPMG LLP, the current independent registered public accounting firm of the Company (the “KPMG”), informed the Company that it will not stand for re-appointment for the Company’s 2025 annual audit. The Company anticipates that KPMG will continue to review its quarterly interim financial results through the first two http://www.streetinsider.com/Globe+Newswire/Aptose+Announces+Auditor+Not+Standing+for+Re-Appointment/24676773.html Wed, 23 Apr 2025 17:00:00 -0400 A.21388897 A.36549092 APS APTO O.00674004 O.01848302 O.48400419 http://www.streetinsider.com/Globe+Newswire/Aptose+Announces+Auditor+Not+Standing+for+Re-Appointment/24676773.html <p align="justify">SAN DIEGO and TORONTO, April 23, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX:APS), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), announces that effective on April 15, 2025, KPMG LLP, the current independent registered public accounting firm of the Company (the “KPMG”), informed the Company that it will not stand for re-appointment for the Company’s 2025 annual audit. The Company anticipates that KPMG will continue to review its quarterly interim financial results through the first two http://www.streetinsider.com/Globe+Newswire/Aptose+Announces+Auditor+Not+Standing+for+Re-Appointment/24676773.html Wed, 23 Apr 2025 17:00:00 -0400 A.21388897 A.36549092 APS APTO O.00674004 O.01848302 O.48400419 http://www.streetinsider.com/Globe+Newswire/Aptose+Announces+Auditor+Not+Standing+for+Re-Appointment/24676773.html <p align="justify">SAN DIEGO and TORONTO, April 23, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX:APS), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), announces that effective on April 15, 2025, KPMG LLP, the current independent registered public accounting firm of the Company (the “KPMG”), informed the Company that it will not stand for re-appointment for the Company’s 2025 annual audit. The Company anticipates that KPMG will continue to review its quarterly interim financial results through the first two http://www.streetinsider.com/Globe+Newswire/Aptose+Announces+Auditor+Not+Standing+for+Re-Appointment/24676773.html Wed, 23 Apr 2025 17:00:00 -0400 A.21388897 A.36549092 APS APTO O.00674004 O.01848302 O.48400419 http://www.streetinsider.com/Globe+Newswire/Aptose+Announces+Auditor+Not+Standing+for+Re-Appointment/24676773.html <p align="justify">SAN DIEGO and TORONTO, April 23, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX:APS), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), announces that effective on April 15, 2025, KPMG LLP, the current independent registered public accounting firm of the Company (the “KPMG”), informed the Company that it will not stand for re-appointment for the Company’s 2025 annual audit. The Company anticipates that KPMG will continue to review its quarterly interim financial results through the first two http://www.streetinsider.com/Globe+Newswire/Aptose+Announces+Auditor+Not+Standing+for+Re-Appointment/24676773.html Wed, 23 Apr 2025 17:00:00 -0400 A.21388897 A.36549092 APS APTO O.00674004 O.01848302 O.48400419 http://www.streetinsider.com/Globe+Newswire/Aptose+Announces+Auditor+Not+Standing+for+Re-Appointment/24676773.html <p align="justify">SAN DIEGO and TORONTO, April 23, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX:APS), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), announces that effective on April 15, 2025, KPMG LLP, the current independent registered public accounting firm of the Company (the “KPMG”), informed the Company that it will not stand for re-appointment for the Company’s 2025 annual audit. The Company anticipates that KPMG will continue to review its quarterly interim financial results through the first two http://www.streetinsider.com/Globe+Newswire/Aptose+Announces+Auditor+Not+Standing+for+Re-Appointment/24676773.html Wed, 23 Apr 2025 17:00:00 -0400 A.21388897 A.36549092 APS APTO O.00674004 O.01848302 O.48400419 http://www.streetinsider.com/Globe+Newswire/Aptose+Announces+Auditor+Not+Standing+for+Re-Appointment/24676773.html <p align="justify">SAN DIEGO and TORONTO, April 23, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX:APS), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), announces that effective on April 15, 2025, KPMG LLP, the current independent registered public accounting firm of the Company (the “KPMG”), informed the Company that it will not stand for re-appointment for the Company’s 2025 annual audit. The Company anticipates that KPMG will continue to review its quarterly interim financial results through the first two http://www.streetinsider.com/Globe+Newswire/Aptose+Announces+Auditor+Not+Standing+for+Re-Appointment/24676773.html Wed, 23 Apr 2025 17:00:00 -0400 A.21388897 A.36549092 APS APTO O.00674004 O.01848302 O.48400419 http://www.streetinsider.com/Press+Releases/Aptose+to+Present+at+the+2025+Bloom+Burton+%26amp%3B+Co.+Healthcare+Investor+Conference/24671800.html <p align="justify">SAN DIEGO and TORONTO, April 23, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced that the Aptose management team will participate in the 2025 Bloom Burton &amp; Co. Healthcare Investor Conference being held in Toronto, May 5-6, 2025.</p> <p align="justify">Dr. William G. Rice, Chairman, President and CEO of Aptose, will present on May 5, 2025 and will be hosting one-on-one meetings during the conference. To http://www.streetinsider.com/Press+Releases/Aptose+to+Present+at+the+2025+Bloom+Burton+%26amp%3B+Co.+Healthcare+Investor+Conference/24671800.html Wed, 23 Apr 2025 07:30:00 -0400 APS APTO O.00674004 http://www.streetinsider.com/Press+Releases/Aptose+to+Present+at+the+2025+Bloom+Burton+%26amp%3B+Co.+Healthcare+Investor+Conference/24671800.html <p align="justify">SAN DIEGO and TORONTO, April 23, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced that the Aptose management team will participate in the 2025 Bloom Burton &amp; Co. Healthcare Investor Conference being held in Toronto, May 5-6, 2025.</p> <p align="justify">Dr. William G. Rice, Chairman, President and CEO of Aptose, will present on May 5, 2025 and will be hosting one-on-one meetings during the conference. To http://www.streetinsider.com/Press+Releases/Aptose+to+Present+at+the+2025+Bloom+Burton+%26amp%3B+Co.+Healthcare+Investor+Conference/24671800.html Wed, 23 Apr 2025 07:30:00 -0400 APS APTO O.00674004 http://www.streetinsider.com/Press+Releases/Aptose+to+Present+at+the+2025+Bloom+Burton+%26amp%3B+Co.+Healthcare+Investor+Conference/24671800.html <p align="justify">SAN DIEGO and TORONTO, April 23, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced that the Aptose management team will participate in the 2025 Bloom Burton &amp; Co. Healthcare Investor Conference being held in Toronto, May 5-6, 2025.</p> <p align="justify">Dr. William G. Rice, Chairman, President and CEO of Aptose, will present on May 5, 2025 and will be hosting one-on-one meetings during the conference. To http://www.streetinsider.com/Press+Releases/Aptose+to+Present+at+the+2025+Bloom+Burton+%26amp%3B+Co.+Healthcare+Investor+Conference/24671800.html Wed, 23 Apr 2025 07:30:00 -0400 APS APTO O.00674004 http://www.streetinsider.com/Globe+Newswire/Aptose+to+Present+at+the+2025+Bloom+Burton+%26amp%3B+Co.+Healthcare+Investor+Conference/24671800.html <p align="justify">SAN DIEGO and TORONTO, April 23, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced that the Aptose management team will participate in the 2025 Bloom Burton &amp; Co. Healthcare Investor Conference being held in Toronto, May 5-6, 2025.</p> <p align="justify">Dr. William G. Rice, Chairman, President and CEO of Aptose, will present on May 5, 2025 and will be hosting one-on-one meetings during the conference. To http://www.streetinsider.com/Globe+Newswire/Aptose+to+Present+at+the+2025+Bloom+Burton+%26amp%3B+Co.+Healthcare+Investor+Conference/24671800.html Wed, 23 Apr 2025 07:30:00 -0400 APS APTO O.00674004 http://www.streetinsider.com/Globe+Newswire/Aptose+to+Present+at+the+2025+Bloom+Burton+%26amp%3B+Co.+Healthcare+Investor+Conference/24671800.html <p align="justify">SAN DIEGO and TORONTO, April 23, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced that the Aptose management team will participate in the 2025 Bloom Burton &amp; Co. Healthcare Investor Conference being held in Toronto, May 5-6, 2025.</p> <p align="justify">Dr. William G. Rice, Chairman, President and CEO of Aptose, will present on May 5, 2025 and will be hosting one-on-one meetings during the conference. To http://www.streetinsider.com/Globe+Newswire/Aptose+to+Present+at+the+2025+Bloom+Burton+%26amp%3B+Co.+Healthcare+Investor+Conference/24671800.html Wed, 23 Apr 2025 07:30:00 -0400 APS APTO O.00674004